期刊文献+

阿托伐他汀对80例急性脑梗死患者血清中妊娠相关蛋白A和基质金属蛋白酶的影响 被引量:5

原文传递
导出
摘要 目的探讨阿托伐他汀对急性脑梗死患者血清中妊娠相关蛋白A(PAPP-A)及基质金属蛋白酶-8(MMP-8)水平的影响,观察其对颈动脉易损斑块的消退作用及评估卒中再发风险。方法将160例经颈动脉超声检查的急性脑梗死患者均分为颈动脉稳定斑块组(对照组)和颈动脉易损斑块组(治疗组),易损斑块组抽血检查后均分为阿托伐他汀低、高剂量组(10、40mg·d-1)。比较治疗前及治疗后4周各组血清中PAPP-A和MMP-8的水平;观察治疗前及治疗后12个月颈动脉的内-中膜厚度(IMT值)、斑块Crouse积分及斑块回声的变化。结果治疗前,阿托伐他汀低、高剂量血清中PAPP-A和MMP-8的水平均高于对照组,但两组间血清中PAPP-A和MMP-8的水平差异无显著性。治疗后4周,阿托伐他汀高剂量组血清中PAPP-A和MMP-8的水平均显著低于低剂量组(P<0.01)。治疗12个月后,阿托伐他汀低、高剂量组的IMT值和颈动脉斑块Crouse积分较治疗前减少,且高剂量组的两项指标低于低剂量组,高剂量组低回声斑块数量较低剂量组明显减少,差异均具有显著性(P<0.01)。结论血清中PAPP-A和MMP-8的水平可作为评估颈动脉粥样硬化斑块易损性的血清学指标,强化他汀类药物调脂治疗能迅速降低脑梗死患者血清中PAPP-A和MMP-8的水平,可逆转和稳定斑块,降低卒中再发风险。
出处 《华西药学杂志》 CAS CSCD 北大核心 2013年第6期647-649,共3页 West China Journal of Pharmaceutical Sciences
基金 武汉市卫生局科研资助项目(编号:WX10C23)
  • 相关文献

参考文献2

二级参考文献21

共引文献3772

同被引文献64

  • 1李志彬,胡健.阿托伐他汀对ACS患者可溶性血管细胞黏附分子-1与P-选择素的影响[J].中国老年学杂志,2007,27(9):870-871. 被引量:1
  • 2Prabhakaran S, Romano JG. Current diagnosis and manage- ment of symptomatic intracranial atherosclerotic disease[ J ]. Curr Opin Neurol, 201.2, 25 : 18-26.
  • 3Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of in- tensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized con- trolled trial[ J]. JAMA, 2004, 291(9) : 1071-1080.
  • 4Jadad AR, Moore RA, Carroll D, et al. Assessing the qual- ity of reports of randomized clinical trials : is blinding neces- sary? [J]. Control Clin Trials, 1996, 17(1): 1-12.
  • 5Wells G, Sultan S, Chen L, et al. Indirect evidence : indirect treatment comparisons in meta-analysis [ M ]. Ottawa: Canadi- an Agency for Drugs and Technologies in Health, 2009.
  • 6Zhou P, Lu Z, Gao P,et al. Efficacy and safety of intensive statin therapy in Chinese patients with atherosclerotic in- tracranial arterial stenosis: a single-center, randomized, sin- gle-blind, parallel-group study with one-year follow-up [ J ].Clin Neurol Neurosur g , 2014,120:6-13.
  • 7Yu CM, Zhang Q, Lain L, et al. Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid inti- mal-medial thickness in patients with coronary heart disease [J]. Heart, 2007, 93 (8) : 933-939.
  • 8Zhang X, Wang H, Liu S, et al. Intensive-dose atorvastatin regimen halts progression of atherosclerotic plaques in new- onset unstable angina with borderline vulnerable plaque le- sions[J]. J Cardiovasc Pharmacol Ther , 2013,18(2) :119- 125.
  • 9Waters DD, Larosa JC, Barter P, et al. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study [ J ]. J Am Coll Cardiol, 2006,48 (9) : 1793-1799.
  • 10Newman C, Tsai J, Szarek M, et al. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trims in 14,236 patients[J]. Am J Cardiol, 2006, 97(1) ..61-67.

引证文献5

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部